WuXi AppTec
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. The founder is Ge Li. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Research
Healthcare, Technology, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan
Tianci materials: the net profit in the first two months increased by about 470% year-on-year
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
For half a day, the main funds increased their positions in the power equipment sector and sold off bank stocks